Hospital admissions/visits associated with drug-drug interactions: A systematic review and meta-analysis

Pharmacoepidemiology and Drug Safety

Volumn 23, Issue 5, 2014, Pages 489-497

  Dechanont, Supinya ^a   Maphanta, Sirada ^a   Butthum, Bodin ^a   Kongkaew, Chuenjid ^a  

^a NARESUAN UNIVERSITY   (Thailand)

Author keywords

Adverse drug reaction; Drug interaction; Hospital admissions; Hospital visits; Pharmacoepidemiology

Indexed keywords

ACETYLSALICYLIC ACID; ATENOLOL; DIGOXIN; HYDROCHLOROTHIAZIDE; LISINOPRIL; NONSTEROID ANTIINFLAMMATORY AGENT; WARFARIN;

ARTICLE; DRUG INTERACTION; ELECTRONIC MEDICAL RECORD; HOSPITAL ADMISSION; HUMAN; INTERVIEW; META ANALYSIS; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; POPULATION; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; SCREENING; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; DRUG SURVEILLANCE PROGRAM; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HOSPITALIZATION; STATISTICS AND NUMERICAL DATA;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DRUG INTERACTIONS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HOSPITALIZATION; HUMANS; PREVALENCE;

EID: 84898047055     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3592     Document Type: Article

References (46)

1. Baxter K. Stockley's Drug Interactions (9th edn). Pharmaceutical Press: London, 2010.
2. Bjerrum L, Lopez-Valcarcel BG, Petersen G. Risk factors for potential drug interactions in general practice. Eur J Gen Pract 2008; 14: 23-29. DOI:10.1080/13814780701815116002E
3. Egger SS, Ratz Bravo AE, Hess L, Schlienger RG, Krahenbuhl S. Age-related differences in the prevalence of potential drug-drug interactions in ambulatory dyslipidaemic patients treated with statins. Drugs Aging 2007; 24: 429-440. DOI:10.2165/00002512-200724050-00006.
4. Heiningger-Rothbucher D, Bischinger S, Ulmer H, Pechlaner C, Speer G, Wiedermann CJ. Incidence and risk of potential adverse drug interactions in the emergency room. Resuscitation 2001; 49(3): 283-288.
5. Prince BS, Goetz CM, Rihn TL, Olsky M. Drug related emergency department visits and hospital admissions. Am J Hosp Pharm 1992; 49: 1696-1700.
6. McDonnell PJ, Jacobs MR. Hospital admissions resulting from preventable adverse drug reactions. Ann Pharmocother 2002; 36: 1331-1336. DOI:10.1345/aph.1A333.
7. Peyriere H, Cassan S, Floutard E, et al. Adverse drug events associated with hospital admission. Ann Pharmocother 2003; 37: 5-11. doi:10.1345/aph.1C126.
8. Shad MU, Marsh C, Preskorn SH. The economic consequences of a drug-drug interaction. J Clin Psychopharmacol 2001; 21: 119-120.
9. Moura C, Acurcio F, Belo N. Drug-drug interactions associated with length of stay and cost of hospitalization. J Pharm Pharmaceut Sci 2009; 12: 266-272.
10. Yee JL, Hasson NK, Schreiber DH. Drug-related emergency department visits in an elderly Veteran population. Ann Pharmacother 2005; 39: 1990-1995. DOI:10.1345/aph.1E541.
11. Vonbach P, Dubied A, Krahenbuhl S, Beer JH. Prevalence of drug-drug interactions at hospital entry and during hospital stay of patients in internal medicine. Eur J Intern Med 2008; 19: 413-420. doi:10.1016/j.ejim.2007.12.002.
12. Kohler GI, Bode-Boger SM, Busse R, Hoopmann M, Welte T, Boger RH. Drug-drug interactions in medical patients: effects of in-hospital treatment and relation to multiple drug use. Int J Clin Pharmacol Ther 2000; 38: 504-513.
13. Reimche L, Forster AJ, van Walraven C. Incidence and contributors to potential drug-drug interactions in hospitalized patients. J Clin Pharmacol 2011; 51: 1043-1050. DOI:10.1177/0091270010378858.
14. Tavakoli-Ardakania M, Kazemian K, Salamzadeh J, Mehdizadeh M. Potential of drug interactions among hospitalized cancer patients in a developing country. Iran J Pharm Res 2013; 12: 171-178.
15. Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18820 patients. Br Med J 2004; 329: 15-19. DOI: http://dx.doi.org/10.1136/bmj.329.7456.15.
16. Peyriere H, Cassan S, Floutard E, et al. Adverse drug events associated with hospital admission. Ann Pharmocother 2003; 37: 5-11. DOI:10.1345/aph.1C126.
17. Juurlink DN, Mamdani M, Kopp A, Laupacis A, Redelmeier DA. Drug-drug interaction among elderly patients hospitalized for drug toxicity. JAMA 2003; 289: 1652-1658. DOI:10.1001/jama.289.13.1652.
18. Aparasu R, Baer R, Aparasu A. Clinically important potential drug-drug interactions in outpatient settings. Res Social Adm Pharm 2007; 3: 426-437. DOI:10.1016/j.sapharm.2006.12.002.
19. Dhabali AAH, Awang R, Zyoud SH. Clinically important drug-drug interactions in primary care. J Clin Pharm 2012; 37: 426-430. DOI:10.1111/j.1365-2710.2011.01314.x.
20. Becker ML, Kallewaard M, Caspers PWJ, Visser LE, Leufkens HGM, Stricker BHC. Hospitalisations and emergency department visits due to drug-drug interactions: a literature review. Pharmacoepidemiol Drug Saf 2007; 16: 641-651. DOI:10.1002/pds.1351.
21. Mirosevic Skvrce N, Macolic Sarinic V, Mucalo I, Krnic D, Bozina N, Tomic S. Adverse drug reactions caused by drugdrug interactions reported to Croatian Agency for Medicinal Products andMedical Devices: a retrospective observational study. Croat Med J 2011; 52: 604-614.
22. Karas S. The potential for drug interactions. Ann Emerg Med 1981; 10: 627-630.
23. Higgins J, Altman D. Assessing risk of bias in included studies. In Cochrane Handbook for Systematic Reviews of Interventions, Higgins JPT, Green S (eds.). John Wiley & Sons Ltd: West Sussex, 2008; 187-235.
24. Huic M, Mucolic V, Vrhovac B, Francetic I, Bakran I, Giljanovic S. Adverse drug reactions resulting in hospital admission. Int J Clin Pharmacol Ther 1994; 32: 675-682.
25. Odar-Cederlof I, Oskarsson P, Ohlen G, et al. Adverse drug effect as cause of hospital admission. Common drugs are the major part according to the cross-sectional study. Lakartidningen 2008; 105: 890-893.
26. Raschetti R, Morgutti M, Menniti-Ippolito F, et al. Suspected adverse drug events requiring emergency department visits or hospital admissions. Eur J Clin Pharmacol 1999; 54: 959-963. DOI:10.1007/s002280050582.
27. Rivkin A. Admissions to a medical intensive care unit related to adverse drug reactions. Am J Health-Syst Pharm 2007; 64: 1840-1843. DOI:10.2146/ajhp060641.
28. Stanton LA, Peterson GM, Rumble RH, Cooper GM, Polack AE. Drug-related admissions to an Australian hospital. J Clin Pharm Ther 1994; 19: 341-347. DOI:10.1111/j.1365-2710.1994.tb00691.x.
29. Fokter N, Mozina M, Brvar M. Potential drug-drug interactions and admissions due to drug-drug interactions in patients treated in medical departments. Wien Klin Wochenschr 2010; 122: 81-88. doi:10.1007/s00508-009-1251-2.
30. Fryckstedt J, Asker-Hagelberg C. Drug-related problems common in the emergency department of internal medicine. The cause of admission in almost every third patient according to quality follow-up. Lakartidningen 2008; 105: 894-898.
31. von Euler M, Eliasson E, Ohlen G, Bergman U. Adverse drug reactions causing hospitalization can be monitored from computerized medical records and thereby indicate the quality of drug utilization. Pharmacoepidemiol Drug Saf 2006; 15: 179-184. DOI:10.1002/pds.1154.
32. Smith KM, McAdams JW, Frenia ML, Todd MW. Drug-related problems in emergency department patients. Am J Health-Syst Pharm 1997; 54: 295-298.
33. Ko Y, Malone DC, Skrepnek GH, et al. Prescribers' knowledge of and sources of information for potential drug-drug interactions: a postal survey of US prescribers. Drug Saf 2008; 31: 525-536. DOI:10.2165/00002018-200831060-00007.
34. Hazlet TK, Lee TA, Hansten PD, Horn JR. Performance of community pharmacy drug interaction software. J Am Pharm Assoc 2001; 41: 200-204.
35. Abarca J, Colon LR, Wang VS, Malone DC, Murphy JE, Armstrong EP. Evaluation of the performance of drug-drug interaction screening software in community and hospital pharmacies. J Manag Care Pharm 2006; 12: 383-389.
36. Qato DM, Alexander GC, Conti RM, Johnson M, Schumm P, Lindau ST. Use of prescription and over-the-counter medications and dietary supplements among older adults in the United State. JAMA 2008; 24: 2867-2878. DOI:10.1001/jama.2008.892.
37. Kwan J, Sandercock P. In-hospital care pathways for stroke. Cochrane Database Syst Rev 2004; 4: CD002924.
38. Nagurney JT, Brown DFM, Sane S, Weiner JB, Wang AC, Chang Y. The accuracy and completeness of data collected by prospective and retrospective methods. Acad Emerg Med 2005; 12: 884-895. DOI:10.1197/j.aem.2005.04.021.
39. National initiative for children's health care quality project advisory committee. Principles of patient safety in pediatrics. Pediatric 2001; 107: 1473-1475. DOI:10.1542/peds.107.6.1473.
40. Mallet L, Spinewine A, Huang A. The challenge of managing drug interactions in elderly people. Lancet 2007; 370: 185-191.
41. Vandvik PO, Lincoff AM, Gore JM, et al. Primary and secondary prevention of cardiovascular disease: American college of chest physicians evidence-based clinical practice guidelines (9th edition). Chest 2012; 141: e637S-e668S. DOI:10.1378/chest.11-2306.
42. th ed., Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM (eds.). McGraw-Hill: New York; 2008. pp. 569-587.
43. Marcus FI. Pharmacokinetic interactions between digoxin and other drugs. J Am Coll Cardiol 1985; 5: 82A-90A. doi:10.1016/S0735-1097(85)80466-6.
44. Nademanee K, Kannan R, Hendrickson J, Ookhtens M, Kay I, Singh BN. Amiodarone-digoxin interaction: clinical significance, time course of development, potential pharmacokinetic mechanism and therapeutic implications. J Am Coll Cardiol 1984; 4: 111-116. DOI:10/1016/S0735-1097(84)80327-7.
45. Klein HO, Lang R, Weiss E, et al. The influence of verapamil on serum digoxin concentration. Circulation 1982; 65: 998-1003. DOI:10.1161/01.CIR.65.5.998.
46. Hart RG, Tonarelli SB, Pearce LA. Avoiding central nervous system bleeding during antithrombotic therapy: recent data and ideas. Stroke 2005; 36: 1588-1593. DOI:10.1161/01.STR.0000170642.39876.f2.